Showing results (101-110 of 126) with videos related to

Sort By:
Pageof 13
Gut|January 30, 2023
Phenotypic CD8 T cell profiling in chronic hepatitis B to predict HBV-specific CD8 T cell susceptibility to functional restoration in vitroMarzia Rossi, Andrea Vecchi, Camilla Tiezzi, et al.
Expert Opinion on Biological Therapy|December 13, 2024
Trajectories of biologic drug use before, during and after pregnancy: an Italian cohort study from the VALORE projectSara Lopes, Michela Servadio, Andrea Spini, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|February 12, 2023
Profiling the risk of hepatocellular carcinoma after long-term HCV eradication in patients with liver cirrhosis in the PITER cohortLoreta A Kondili, Maria Giovanna Quaranta, Luisa Cavalletto, et al.
Hepatology International|April 13, 2020
Advanced liver disease outcomes after hepatitis C eradication by human immunodeficiency virus infection in PITER cohortMaria Giovanna Quaranta, Luigina Ferrigno, Monica Monti, et al.
Plos One|January 3, 2018
Correction: Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort StudyLoreta A Kondili, Giovanni Battista Gaeta, Donatella Ieluzzi, et al.
Gut|July 20, 2024
HBcrAg values may predict virological and immunological responses to pegIFN-α in NUC-suppressed HBeAg-negative chronic hepatitis BAndrea Vecchi, Marzia Rossi, Camilla Tiezzi, et al.
Expert Review of Vaccines|April 7, 2022
Effectiveness of an mRNA vaccine booster dose against SARS-CoV-2 infection and severe COVID-19 in persons aged ≥60 years and other high-risk groups during predominant circulation of the delta variant in Italy, 19 July to 12 December 2021Massimo Fabiani, Maria Puopolo, Antonietta Filia, et al.
Plos One|March 1, 2017
Real-life data on potential drug-drug interactions in patients with chronic hepatitis C viral infection undergoing antiviral therapy with interferon-free DAAs in the PITER Cohort StudyLoreta A Kondili, Giovanni Battista Gaeta, Donatella Ieluzzi, et al.
Viruses|May 25, 2024
Reduction of the Risk of Hepatocellular Carcinoma over Time Using Direct-Acting Antivirals: A Propensity Score Analysis of a Real-Life Cohort (PITER HCV)Maria Giovanna Quaranta, Luisa Cavalletto, Francesco Paolo Russo, et al.
The Lancet. Rheumatology|August 25, 2020
Tocilizumab in patients with severe COVID-19: a retrospective cohort studyGiovanni Guaraldi, Marianna Meschiari, Alessandro Cozzi-Lepri, et al.
Pageof 13